Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non–muscle-invasive Bladder Cancer (BRIDGE)

Max Kates; Xiangying Chu; Noah Hahn; Eugene Pietzak; Angela Smith; Daniel H. Shevrin; Paul Crispen; Stephen B. Williams; Siamak Daneshmand; Vignesh T. Packiam; Sima Porten; Mary E. Westerman; Lynne I. Wagner; Michael Carducci

doi:10.1016/j.euf.2023.06.006

Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non–muscle-invasive Bladder Cancer (BRIDGE)

Max Kates, Xiangying Chu, Noah Hahn, Eugene Pietzak, Angela Smith, Daniel H. Shevrin, Paul Crispen, Stephen B. Williams, Siamak Daneshmand, Vignesh T. Packiam, Sima Porten, Mary E. Westerman, Lynne I. Wagner, Michael Carducci

School of Medicine

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	561-563
Number of pages	3
Journal	European Urology Focus
Volume	9
Issue number	4
DOIs	https://doi.org/10.1016/j.euf.2023.06.006
State	Published - Jul 2023

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.euf.2023.06.006

Cite this

Kates, M., Chu, X., Hahn, N., Pietzak, E., Smith, A., Shevrin, D. H., Crispen, P., Williams, S. B., Daneshmand, S., Packiam, V. T., Porten, S., Westerman, M. E., Wagner, L. I., & Carducci, M. (2023). Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non–muscle-invasive Bladder Cancer (BRIDGE). European Urology Focus, 9(4), 561-563. https://doi.org/10.1016/j.euf.2023.06.006

Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non–muscle-invasive Bladder Cancer (BRIDGE). / Kates, Max; Chu, Xiangying; Hahn, Noah et al.
In: European Urology Focus, Vol. 9, No. 4, 07.2023, p. 561-563.

Research output: Contribution to journal › Comment/debate › peer-review

Kates, M, Chu, X, Hahn, N, Pietzak, E, Smith, A, Shevrin, DH, Crispen, P, Williams, SB, Daneshmand, S, Packiam, VT, Porten, S, Westerman, ME, Wagner, LI & Carducci, M 2023, 'Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non–muscle-invasive Bladder Cancer (BRIDGE)', European Urology Focus, vol. 9, no. 4, pp. 561-563. https://doi.org/10.1016/j.euf.2023.06.006

Kates M, Chu X, Hahn N, Pietzak E, Smith A, Shevrin DH et al. Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non–muscle-invasive Bladder Cancer (BRIDGE). European Urology Focus. 2023 Jul;9(4):561-563. doi: 10.1016/j.euf.2023.06.006

@article{09861b47e30949f78df958ab41ba5c37,

title = "Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Gu{\'e}rin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-na{\"i}ve High-grade Non–muscle-invasive Bladder Cancer (BRIDGE)",

author = "Max Kates and Xiangying Chu and Noah Hahn and Eugene Pietzak and Angela Smith and Shevrin, {Daniel H.} and Paul Crispen and Williams, {Stephen B.} and Siamak Daneshmand and Packiam, {Vignesh T.} and Sima Porten and Westerman, {Mary E.} and Wagner, {Lynne I.} and Michael Carducci",

note = "Funding Information: Acknowledgments: This study is being conducted by the ECOG-ACRIN Cancer Research Group and is supported by the US National Institutes of Health/National Cancer Institute under grants U10CA180820, U10CA180794, UG1CA180830, UG1CA189854, UG1CA233180, UG1CA233196, UG1CA233290, and UG1CA233373. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.",

year = "2023",

month = jul,

doi = "10.1016/j.euf.2023.06.006",

language = "English (US)",

volume = "9",

pages = "561--563",

journal = "European Urology Focus",

issn = "2405-4569",

publisher = "Elsevier B.V.",

number = "4",

}

TY - JOUR

T1 - Background and Update for ECOG-ACRIN EA8212

T2 - A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non–muscle-invasive Bladder Cancer (BRIDGE)

AU - Kates, Max

AU - Chu, Xiangying

AU - Hahn, Noah

AU - Pietzak, Eugene

AU - Smith, Angela

AU - Shevrin, Daniel H.

AU - Crispen, Paul

AU - Williams, Stephen B.

AU - Daneshmand, Siamak

AU - Packiam, Vignesh T.

AU - Porten, Sima

AU - Westerman, Mary E.

AU - Wagner, Lynne I.

AU - Carducci, Michael

N1 - Funding Information: Acknowledgments: This study is being conducted by the ECOG-ACRIN Cancer Research Group and is supported by the US National Institutes of Health/National Cancer Institute under grants U10CA180820, U10CA180794, UG1CA180830, UG1CA189854, UG1CA233180, UG1CA233196, UG1CA233290, and UG1CA233373. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

PY - 2023/7

Y1 - 2023/7

UR - http://www.scopus.com/inward/record.url?scp=85164372758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85164372758&partnerID=8YFLogxK

U2 - 10.1016/j.euf.2023.06.006

DO - 10.1016/j.euf.2023.06.006

M3 - Comment/debate

C2 - 37422371

AN - SCOPUS:85164372758

SN - 2405-4569

VL - 9

SP - 561

EP - 563

JO - European Urology Focus

JF - European Urology Focus

IS - 4

ER -

Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non–muscle-invasive Bladder Cancer (BRIDGE)

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this